BRPI0408226A - sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna - Google Patents
sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìnaInfo
- Publication number
- BRPI0408226A BRPI0408226A BRPI0408226-5A BRPI0408226A BRPI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- iminoethyl
- aminoethyl
- maleate hydrochloride
- cysteine
- Prior art date
Links
- -1 1-iminoethyl Chemical group 0.000 title abstract 5
- FXNSRODXMVUCNJ-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrochloride Chemical compound Cl.OC(=O)\C=C/C(O)=O FXNSRODXMVUCNJ-ODZAUARKSA-N 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 abstract 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
"SAL CRISTALINO DE CLORIDRATO DE MALEATO DE S-¢2-¢(1-IMINOETIL)AMINO!ETIL-2-METIL-L-CISTEìNA". é apresentada um novo sal misto de S-¢2-¢(l-iminoetil)aminoetil!2-metii-L-cisteína. O novo sal misto, cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína pode ser preparado para formar cristais que podem ser arranjados geralmente como aglomerados empacotados ordenadamente, os quais são particularmente úteis na preparação de composições farmacêuticas. Tais composições farmacêuticas são também descritas, bem como os métodos para preparar cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína cristalino e métodos de tratar condições caracterizadas por uma sobre expressão em óxido nítrico da isoforma induzida da óxido nítrico sintase utilizando o cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45349603P | 2003-03-11 | 2003-03-11 | |
| PCT/IB2004/000678 WO2004080956A1 (en) | 2003-03-11 | 2004-03-04 | S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408226A true BRPI0408226A (pt) | 2006-03-01 |
Family
ID=32990778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408226-5A BRPI0408226A (pt) | 2003-03-11 | 2004-03-04 | sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20050038120A1 (pt) |
| EP (1) | EP1603872B1 (pt) |
| JP (1) | JP4794433B2 (pt) |
| KR (2) | KR20090048521A (pt) |
| CN (1) | CN100460387C (pt) |
| AR (1) | AR043521A1 (pt) |
| AT (1) | ATE509909T1 (pt) |
| AU (1) | AU2004220266B2 (pt) |
| BR (1) | BRPI0408226A (pt) |
| CA (1) | CA2518745C (pt) |
| CL (1) | CL2004000472A1 (pt) |
| CO (1) | CO5611122A2 (pt) |
| CY (1) | CY1112461T1 (pt) |
| DK (1) | DK1603872T3 (pt) |
| ES (1) | ES2363001T3 (pt) |
| GT (1) | GT200400040A (pt) |
| IL (1) | IL170554A (pt) |
| MX (1) | MXPA05008674A (pt) |
| NL (1) | NL1025691C2 (pt) |
| NO (1) | NO20054645L (pt) |
| NZ (1) | NZ574218A (pt) |
| PA (1) | PA8597701A1 (pt) |
| PE (1) | PE20050309A1 (pt) |
| PL (1) | PL1603872T3 (pt) |
| PT (1) | PT1603872E (pt) |
| RU (1) | RU2357953C2 (pt) |
| SG (1) | SG155782A1 (pt) |
| SI (1) | SI1603872T1 (pt) |
| TW (1) | TWI352076B (pt) |
| UY (1) | UY28229A1 (pt) |
| WO (1) | WO2004080956A1 (pt) |
| ZA (1) | ZA200506459B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6094101A (en) * | 1999-03-17 | 2000-07-25 | Tropian, Inc. | Direct digital frequency synthesis enabling spur elimination |
| PT1793187E (pt) * | 2004-09-21 | 2012-03-05 | Joan Vives Iglesias | Processo e máquina destinados à sinterização e/ou secagem de materiais em pó utilizando uma radiação infravermelha |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9103572D0 (sv) * | 1991-11-29 | 1991-11-29 | Astra Ab | Organic salts of n,n'-diacetyl cystine |
| DE69529101T2 (de) * | 1994-06-15 | 2003-11-13 | Wellcome Found | Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren |
| MY117948A (en) * | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| GEP20094625B (en) * | 2000-03-24 | 2009-03-10 | Pharmacia Corp | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| AR031609A1 (es) * | 2000-09-15 | 2003-09-24 | Pharmacia Corp | Derivados de acido 2-amino-2-alquil-3 heptenoico y heptinoico utiles como inhibidores de oxido nitrico sintetasa |
| AR031608A1 (es) * | 2000-09-15 | 2003-09-24 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
-
2004
- 2004-03-04 AT AT04717188T patent/ATE509909T1/de active
- 2004-03-04 EP EP04717188A patent/EP1603872B1/en not_active Expired - Lifetime
- 2004-03-04 AU AU2004220266A patent/AU2004220266B2/en not_active Ceased
- 2004-03-04 CA CA2518745A patent/CA2518745C/en not_active Expired - Fee Related
- 2004-03-04 SG SG200802031-5A patent/SG155782A1/en unknown
- 2004-03-04 NZ NZ574218A patent/NZ574218A/en not_active IP Right Cessation
- 2004-03-04 BR BRPI0408226-5A patent/BRPI0408226A/pt not_active IP Right Cessation
- 2004-03-04 SI SI200431696T patent/SI1603872T1/sl unknown
- 2004-03-04 MX MXPA05008674A patent/MXPA05008674A/es active IP Right Grant
- 2004-03-04 PL PL04717188T patent/PL1603872T3/pl unknown
- 2004-03-04 WO PCT/IB2004/000678 patent/WO2004080956A1/en not_active Ceased
- 2004-03-04 KR KR1020097008258A patent/KR20090048521A/ko not_active Ceased
- 2004-03-04 ES ES04717188T patent/ES2363001T3/es not_active Expired - Lifetime
- 2004-03-04 JP JP2006506318A patent/JP4794433B2/ja not_active Expired - Fee Related
- 2004-03-04 PT PT04717188T patent/PT1603872E/pt unknown
- 2004-03-04 CN CNB200480012896XA patent/CN100460387C/zh not_active Expired - Fee Related
- 2004-03-04 DK DK04717188.9T patent/DK1603872T3/da active
- 2004-03-04 RU RU2005125833/04A patent/RU2357953C2/ru not_active IP Right Cessation
- 2004-03-04 KR KR1020057016858A patent/KR100927911B1/ko not_active Expired - Fee Related
- 2004-03-09 AR ARP040100751A patent/AR043521A1/es not_active Application Discontinuation
- 2004-03-09 CL CL200400472A patent/CL2004000472A1/es unknown
- 2004-03-09 PE PE2004000257A patent/PE20050309A1/es not_active Application Discontinuation
- 2004-03-10 GT GT200400040A patent/GT200400040A/es unknown
- 2004-03-10 TW TW093106315A patent/TWI352076B/zh not_active IP Right Cessation
- 2004-03-10 US US10/797,462 patent/US20050038120A1/en not_active Abandoned
- 2004-03-10 PA PA20048597701A patent/PA8597701A1/es unknown
- 2004-03-11 UY UY28229A patent/UY28229A1/es not_active Application Discontinuation
- 2004-03-11 NL NL1025691A patent/NL1025691C2/nl not_active IP Right Cessation
-
2005
- 2005-08-11 ZA ZA200506459A patent/ZA200506459B/en unknown
- 2005-08-29 IL IL170554A patent/IL170554A/en not_active IP Right Cessation
- 2005-09-09 CO CO05091013A patent/CO5611122A2/es not_active Application Discontinuation
- 2005-10-10 NO NO20054645A patent/NO20054645L/no not_active Application Discontinuation
-
2008
- 2008-12-05 US US12/315,744 patent/US7767850B2/en not_active Expired - Fee Related
-
2011
- 2011-06-06 CY CY20111100540T patent/CY1112461T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| BR0313723A (pt) | Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor | |
| BRPI0409227C1 (pt) | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) | |
| BRPI0510273A (pt) | derivados de tetraazabenzo[e]azuleno e análogos destes | |
| BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
| BR0213612A (pt) | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição | |
| NO20073325L (no) | Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| NO20050649L (no) | Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
| BRPI0410660A (pt) | derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2 | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| BRPI0409627A (pt) | 2-hidróxi-3-diaminoalcanos de fenacila | |
| CA2744756A1 (en) | Monocarbams and their use as antibacterial agent | |
| BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
| BRPI0708278B8 (pt) | forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica | |
| BR0015166A (pt) | Naftopiranos anelados em c5 - c6, com um carbociclo do tipo indeno- ou dihidronaftaleno e composições e matrizes contendo-os | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
| BRPI0411246A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto | |
| BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz | |
| BRPI0502228A (pt) | forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |